Array BioPharma (ARRY) PT Raised to $24 at Jefferies
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $5.05 -2.32%
Rating Summary:
18 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
18 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Jefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.
Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- New Street Research Upgrades Micron Technology (MU) to Buy
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
